Chia PL - Search Results

1

Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort.

Chia PL, Russell P, Asadi K, Thapa B, Gebski V, Murone C, Walkiewicz M, Eriksson U, Scott AM, John T. Chia PL, et al. Lung Cancer. 2020 Dec;150:1-8. doi: 10.1016/j.lungcan.2020.09.022. Epub 2020 Oct 1. Lung Cancer. 2020. PMID: 33035778

2

Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.

Chia PL, Russell PA, Scott AM, John T. Chia PL, et al. Expert Rev Anticancer Ther. 2016 Dec;16(12):1235-1245. doi: 10.1080/14737140.2016.1244008. Epub 2016 Oct 12. Expert Rev Anticancer Ther. 2016. PMID: 27696931 Review.

3

Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort?

John T, Chia PL. John T, et al. Among authors: chia pl. Clin Cancer Res. 2018 Apr 1;24(7):1513-1515. doi: 10.1158/1078-0432.CCR-17-3493. Epub 2018 Jan 19. Clin Cancer Res. 2018. PMID: 29351918

4

Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma.

Chia PL, Scott AM, John T. Chia PL, et al. Expert Opin Drug Deliv. 2019 Apr;16(4):441-451. doi: 10.1080/17425247.2019.1598374. Epub 2019 Apr 18. Expert Opin Drug Deliv. 2019. PMID: 30916586 Review.

5

Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.

Chia PL, Parakh S, Russell P, Gan HK, Asadi K, Gebski V, Murone C, Walkiewicz M, Liu Z, Thapa B, Scott FE, Scott AM, John T. Chia PL, et al. Lung Cancer. 2021 Mar;153:35-41. doi: 10.1016/j.lungcan.2020.12.028. Epub 2020 Dec 31. Lung Cancer. 2021. PMID: 33453471

6

Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.

Chia PL, Parakh S, Tsao MS, Pham NA, Gan HK, Cao D, Burvenich IJG, Rigopoulos A, Reilly EB, John T, Scott AM. Chia PL, et al. Pharmaceuticals (Basel). 2020 Oct 2;13(10):289. doi: 10.3390/ph13100289. Pharmaceuticals (Basel). 2020. PMID: 33023139 Free PMC article.

7

Vortex Keratopathy Presumed Secondary to AZD9291.

Chia PL, John T. Chia PL, et al. J Thorac Oncol. 2015 Dec;10(12):1807-8. doi: 10.1097/JTO.0000000000000634. J Thorac Oncol. 2015. PMID: 26709481 Free article. No abstract available.

8

Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.

Chia PL, Do H, Morey A, Mitchell P, Dobrovic A, John T. Chia PL, et al. Lung Cancer. 2016 Aug;98:29-32. doi: 10.1016/j.lungcan.2016.05.003. Epub 2016 May 11. Lung Cancer. 2016. PMID: 27393503

9

Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).

Chia PL, John T. Chia PL, et al. J Immunother. 2016 Jun;39(5):202-4. doi: 10.1097/CJI.0000000000000121. J Immunother. 2016. PMID: 27163740

10

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.

Chia PL, Mitchell P, Dobrovic A, John T. Chia PL, et al. Clin Epidemiol. 2014 Nov 20;6:423-32. doi: 10.2147/CLEP.S69718. eCollection 2014. Clin Epidemiol. 2014. PMID: 25429239 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters